Cell signaling

ProtoKinetix AAGP® Moves to Whole Organ Transplantation Testing

Retrieved on: 
Friday, August 14, 2020
Health, Other Health, Other Science, General Health, Research, Science, Branches of biology, Biology, Programmed cell death, Apoptosis, Cell signaling, Cellular senescence, Immunology, PKX

ProtoKinetix, Incorporated ( www.protokinetix.com ) (the "Company" or "ProtoKinetix") (OTCQB: PKTX ), a clinical-stage biomedical company, today announced that due to the results that AAGP has achieved over the previous years, we are now moving into whole organ transplantation, open heart surgery and cardiac ischemia treatment testing.

Key Points: 
  • ProtoKinetix, Incorporated ( www.protokinetix.com ) (the "Company" or "ProtoKinetix") (OTCQB: PKTX ), a clinical-stage biomedical company, today announced that due to the results that AAGP has achieved over the previous years, we are now moving into whole organ transplantation, open heart surgery and cardiac ischemia treatment testing.
  • The mechanism of PKX-001 protective activity may in part be explained by its inhibitory effect on cysteine-type endopeptidase activity involved in the apoptotic signaling pathway.
  • PKX-001 had no cytotoxic effect and minimally affected survival and normal functional activity of cardiomyocytes, both in vitro and ex vivo.
  • - Prof. Dr. Thomas Pulinilkunnil, Ph.D.
    PKX-001 is the designation given to the lead drug product molecule of the AAGP family.

Estée Lauder Introduces New Advanced Night Repair Synchronized Multi-Recovery Complex

Retrieved on: 
Wednesday, August 5, 2020
Branches of biology, Biology, Old age, Cell biology, Ageing, Gerontology, Epigenetics, Cell signaling

TORONTO, Aug. 5, 2020 /CNW/ - Backed by an unprecedented new discovery in the scientific field of Epigenetics, Este Lauder introduces the revolutionary new Advanced Night Repair Synchronized Multi-Recovery Complex.

Key Points: 
  • TORONTO, Aug. 5, 2020 /CNW/ - Backed by an unprecedented new discovery in the scientific field of Epigenetics, Este Lauder introduces the revolutionary new Advanced Night Repair Synchronized Multi-Recovery Complex.
  • Advanced Night Repair absorbs fast as it works to reduce the look of multiple signs of aging and helps protect skin from the environmental assaults of modern life.
  • In a breakthrough discovery, Este Lauder identified a specific micro signaling molecule that is essential to skin's natural repair and promotes multiple vital anti-aging pathways.
  • Helps rapidly ignite a dynamic, connected repair network to help promote skin's natural repair processes.

Achieve Announces Patent Granted in the U.S. for Novel Analogs of Cytisinicline for Use in CNS and Addiction Indications

Retrieved on: 
Friday, July 31, 2020
Branches of biology, Neurotransmitters, Ion channels, Nicotinic agonists, Nicotinic acetylcholine receptors, Smoking, Cell signaling, Nicotine, Acetylcholine, Addiction

Cytisinicline is a selective partial agonist of nicotinic acetylcholine receptors (nAChRs), which underlies its activity in nicotine addiction.

Key Points: 
  • Cytisinicline is a selective partial agonist of nicotinic acetylcholine receptors (nAChRs), which underlies its activity in nicotine addiction.
  • nACHRs are more broadly involved in a range of physiological functions, such as cognitive function, learning and memory, emotion and control of movement.
  • Tobacco use is currently the leading cause of preventable death and is responsible for more than eight million deaths annually worldwide1.
  • Achieve's focus is to address the global smoking health and nicotine addiction epidemic through the development and commercialization of cytisinicline.

Strata Oncology Announces Partnership with BioMed Valley Discoveries to Accelerate Enrollment in ERK Inhibitor Study

Retrieved on: 
Wednesday, July 29, 2020
Branches of biology, Signal transduction, Cell biology, Biology, Cell signaling, MAPK/ERK pathway, Mitogen-activated protein kinase, BRAF

BioMed Valley reported positive preliminary Phase I data for ulixertinib in patients harboring MAPK alterations, including atypical BRAF alterations.

Key Points: 
  • BioMed Valley reported positive preliminary Phase I data for ulixertinib in patients harboring MAPK alterations, including atypical BRAF alterations.
  • Under the terms of the agreement and through the Strata Trial, Strata Oncology will identify patients with advanced solid tumors that harbor mutations in the MAPK signaling pathway and meet other eligibility criteria, for consideration of enrollment into BioMed Valley's Phase 2 study.
  • "This partnership with BioMed Valley Discoveries supports our commitment to improving the lives of patients with cancer by providing local access to promising investigational therapies," said Dan Rhodes, Ph.D., CEO of Strata Oncology.
  • David Chao, President & CEO of BioMed Valley Discoveries, commented,"We are delighted to collaboratewith Strata to developourfirst-in-class ERK inhibitor.

CAST Releases New Commentary on "Impacts on Human Health and Safety of Naturally Occurring and Supplemental Hormones in Food Animals"

Retrieved on: 
Monday, July 27, 2020
Branches of biology, Articles, Food and drink, Endocrinology, Food politics, Food science, Cell signaling, Hormone, Signal transduction, Food safety, Agriculture

AMES, Iowa, July 27, 2020 /PRNewswire-PRWeb/ --The Council for Agricultural Sciences and Technology (CAST) has released a new paper, "Impacts on Human Health and Safety of Naturally Occurring and Supplemental Hormones in Food Animals."

Key Points: 
  • AMES, Iowa, July 27, 2020 /PRNewswire-PRWeb/ --The Council for Agricultural Sciences and Technology (CAST) has released a new paper, "Impacts on Human Health and Safety of Naturally Occurring and Supplemental Hormones in Food Animals."
  • Since World War II, the United States has pursued a national policy of an abundant and inexpensive food supply.
  • The authors also discuss the use of hormones to improve cow health, food safety oversight, and human exposure to hormone residues.
  • The commentary, "Impacts on Human Health and Safety of Naturally Occurring and Supplemental Hormones in Food Animals," is available to download for free on CAST's website.

As Evidence of "Hormone Disruptor" Chemical Threats Grows, Experts Call for Stricter Regulation

Retrieved on: 
Wednesday, July 22, 2020
Branches of biology, Biology, Endocrinology, Cell signaling, Hormone, Physiology, Signal transduction, Pesticide

These chemicals are believed to interfere with the function of hormones, signaling compounds made in glands that circulate to influence processes throughout the body.

Key Points: 
  • These chemicals are believed to interfere with the function of hormones, signaling compounds made in glands that circulate to influence processes throughout the body.
  • For example, new findings suggest that PFAS, bisphenols, and certain pesticides may damage semen.
  • He notes that the Environmental Protection Agency established a protocol in the late 1990s to better regulate these chemicals.
  • However, the effort made little headway, Trasande explains, largely because of a perceived lack of conclusive studies and fierce lobbying by the chemical and manufacturing industries.

Senhwa Biosciences's Silmitasertib Receives Rare Pediatric Disease Designation from U.S. FDA for Treatment of Recurrent Sonic Hedgehog Medulloblastoma

Retrieved on: 
Tuesday, July 7, 2020
Branches of biology, Biology, Cell biology, Cell signaling, Orphan drugs, Brain tumor, Chloroarenes, Protein kinase inhibitors, Medulloblastoma, Silmitasertib, Priority review, AbbVie Inc.

Food and Drug Administration(FDA) granted Rare Pediatric Disease (RPD) Designation for its drug Silmitasertib, a Casein Kinase 2 (CK2) inhibitor,being developed as a treatment for recurrent sonic hedgehog (SHH) medulloblastoma.

Key Points: 
  • Food and Drug Administration(FDA) granted Rare Pediatric Disease (RPD) Designation for its drug Silmitasertib, a Casein Kinase 2 (CK2) inhibitor,being developed as a treatment for recurrent sonic hedgehog (SHH) medulloblastoma.
  • With the RPD designation, Senhwa Biosciences is eligible for a Priority Review Voucher (PRV) which can be used for a subsequent marketing application, and may be sold or transferred.
  • In August 2015, AbbVie bought a PRV from United Therapeutics Corp for $350 million which allowed AbbVie to accelerate one of its drug's FDA review process.
  • Treatment for medulloblastoma usually includes surgery, followed by radiation or chemotherapy, or both.Currently there is no targeted drug available.

Brain receptor pulls open electrical gate like a puppet master

Retrieved on: 
Tuesday, June 30, 2020
Branches of biology, Biology, Cell signaling, Cell biology, Membrane biology, Pharmacodynamics, Receptor antagonist, Signal transduction, Receptor

Critical for brain development and function, the receptor converts chemical messages between cells into electrical signals within a neuron.

Key Points: 
  • Critical for brain development and function, the receptor converts chemical messages between cells into electrical signals within a neuron.
  • Unlocking the receptor's ion channel is like working a stringed puppetrock one part of the receptor and slender filaments pull open the channel's gate.
  • Understanding how the receptor works could lead to better treatments for Alzheimer's disease, depression, epilepsy, stroke, or schizophrenia.
  • But if an antagonist binds, the loop loosens so much that the LBD cannot pull open the gate.

Sol-Gel to Present at Virtual BMO 2020 Prescriptions for Success Healthcare Conference

Retrieved on: 
Tuesday, June 16, 2020
Branches of biology, Quinazolines, Organic compounds, Cell signaling, Amines, Astellas Pharma, Erlotinib, Ethers, Genentech, Epidermal growth factor receptor, Growth factor receptor inhibitor

A live audio webcast will be available in the Investors/Events & Presentations section of the Sol-Gel Technologies website at http://ir.sol-gel.com/events-and-presentations .

Key Points: 
  • A live audio webcast will be available in the Investors/Events & Presentations section of the Sol-Gel Technologies website at http://ir.sol-gel.com/events-and-presentations .
  • The webcast replay will also be available at the same link shortly after the conclusion of the event for 30 days.
  • The Companys pipeline also includes SGT-210, an early-stage topical epidermal growth factor receptor inhibitor, erlotinib, for the treatment of punctatepalmoplantar keratoderma, and preclinical assets tapinarof and roflumilast.
  • For additional information, please visit www.sol-gel.com .

Find Therapeutics, a new drug development company dedicated to breakthrough therapies against rare diseases launches in Montreal

Retrieved on: 
Monday, June 8, 2020
Branches of biology, Biology, Signal transduction, Cell signaling, Cell biology, Integral membrane proteins, Protein families, G protein-coupled receptor, Receptor, Allosteric regulation, Raymond C. Stevens, Adhesion G protein-coupled receptor

MONTREAL, June 8, 2020 /CNW Telbec/ -CTI Life Sciences, along with partners adMare BioInnovations, Domain Therapeutics and PeptiMimesis Pharma, have come together to establish a new Montreal-based drug discovery and development company, Find Therapeutics, dedicated to the development of the next generation of GPCR allosteric modulators to treat rare diseases.

Key Points: 
  • MONTREAL, June 8, 2020 /CNW Telbec/ -CTI Life Sciences, along with partners adMare BioInnovations, Domain Therapeutics and PeptiMimesis Pharma, have come together to establish a new Montreal-based drug discovery and development company, Find Therapeutics, dedicated to the development of the next generation of GPCR allosteric modulators to treat rare diseases.
  • "We are very excited about building this new company based on an innovative approach to discover transmembrane GPCR drugs.
  • "We are also very proud of this partnership with members of the life science ecosystem bringing together multiple talents."
  • www.ctisciences.com
    Domain Therapeutics is a biopharmaceutical company dedicated to the discovery and development of new drug candidates targeting G Protein-Coupled Receptors (GPCRs), one of the most important classes of drug targets.